Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5947093 | 0.85 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19BCHE | |
| SCHEMBL5947298 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C19BCHE | |
| SCHEMBL5947283 | 0.84 | BCHE (0.58) | CYP1A2CYP3A4CYP2D6CYP2C19BCHE | |
| SCHEMBL5947560 | 0.83 | KDM4E (0.58) | CYP2D6BCHEHTR2AKMT2ASMPD1 | |
| SCHEMBL5947523 | 0.80 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19BCHE | |
| SCHEMBL5947135 | 0.80 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19BCHE | |
| SCHEMBL5947672 | 0.80 | CYP1A2 (0.70) | CYP1A2CYP3A4CYP2D6CYP2C19BCHE | |
| SCHEMBL5947594 | 0.78 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2D6CYP2C19BCHE | |
| SCHEMBL5947496 | 0.78 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP2C19BCHE | |
| SCHEMBL5947854 | 0.78 | KMT2A (0.71) | HTR2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | claimed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | CYP1A2 530/4885CYP3A4 939/4885CYP2D6 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.